Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Accumulated Expenses (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Accumulated Expenses for 12 consecutive years, with $5.5 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 237.35% year-over-year to $5.5 million; the TTM value through Mar 2026 reached $5.5 million, up 237.35%, while the annual FY2025 figure was $18.1 million, 17.72% up from the prior year.
  • Accumulated Expenses hit $5.5 million in Q1 2026 for Wave Life Sciences, down from $18.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $18.1 million in Q4 2025 and bottomed at $1.1 million in Q3 2023.
  • Average Accumulated Expenses over 5 years is $6.7 million, with a median of $3.5 million recorded in 2022.
  • Year-over-year, Accumulated Expenses tumbled 83.22% in 2022 and then surged 435.27% in 2025.
  • Wave Life Sciences' Accumulated Expenses stood at $17.6 million in 2022, then dropped by 4.12% to $16.8 million in 2023, then decreased by 8.74% to $15.4 million in 2024, then rose by 17.72% to $18.1 million in 2025, then tumbled by 69.47% to $5.5 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $5.5 million, $18.1 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.